Literature DB >> 8612581

Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.

M Resnati1, M Guttinger, S Valcamonica, N Sidenius, F Blasi, F Fazioli.   

Abstract

Physiological concentrations of urokinase plasminogen activator (uPA) stimulated a chemotactic response in human monocytic THP-1 through binding to the urokinase receptor (uPAR). The effect did not require the protease moiety of uPA, as stimulation was achieved also with the N-terminal fragment (ATF), while the 33 kDa low molecular weight uPA was ineffective. Co-immunoprecipitation experiments showed association of uPAR with intracellular kinase(s), as demonstrated by in vitro kinase assays. Use of specific antibodies identified p56/p59hck as a kinase associated with uPAR in THP-1 cell extracts. Upon addition of ATF, p56/p59hck activity was stimulated within 2 min and returned to normal after 30 min. Since uPAR lacks an intracellular domain capable of interacting with intracellular kinase, activation of p56/p59hck must require a transmembrane adaptor. Evidence for this was strongly supported by the finding that a soluble form of uPAR (suPAR) was capable of inducing chemotaxis not only in THP-1 cells but also in cells lacking endogenous uPAR (IC50, 5 pM). However, activity of suPAR require chymotrypsin cleavage between the N-terminal domain D1 and D2 + D3. Chymotrypsin-cleaved suPAR also induced activation of p56/p59hck in THP-1 cells, with a time course comparable with ATF. Our data show that uPA-induced signal transduction takes place via uPAR, involves activation of intracellular tyrosine kinase(s) and requires an as yet undefined adaptor capable of connecting the extracellular ligand binding uPAR to intracellular transducer(s).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612581      PMCID: PMC450067     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  49 in total

1.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

Authors:  T K Vu; D T Hung; V I Wheaton; S R Coughlin
Journal:  Cell       Date:  1991-03-22       Impact factor: 41.582

2.  Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases.

Authors:  Y Uehara; H Fukazawa
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Use and specificity of genistein as inhibitor of protein-tyrosine kinases.

Authors:  T Akiyama; H Ogawara
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor.

Authors:  M T Masucci; N Pedersen; F Blasi
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

5.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

6.  GPI-anchored cell-surface molecules complexed to protein tyrosine kinases.

Authors:  I Stefanová; V Horejsí; I J Ansotegui; W Knapp; H Stockinger
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

7.  Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.

Authors:  E Rønne; N Behrendt; V Ellis; M Ploug; K Danø; G Høyer-Hansen
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

8.  Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.

Authors:  M V Cubellis; P Andreasen; P Ragno; M Mayer; K Danø; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

9.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.

Authors:  N Behrendt; M Ploug; L Patthy; G Houen; F Blasi; K Danø
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

10.  Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes.

Authors:  N Manchanda; B S Schwartz
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

View more
  62 in total

1.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Authors:  Andrew S Gilder; Karra A Jones; Jingjing Hu; Lei Wang; Clark C Chen; Bob S Carter; Steven L Gonias
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

Review 4.  Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Authors:  Hernán Trimarchi
Journal:  World J Nephrol       Date:  2013-11-06

5.  Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction.

Authors:  A Nykjaer; E I Christensen; H Vorum; H Hager; C M Petersen; H Røigaard; H Y Min; F Vilhardt; L B Møller; S Kornfeld; J Gliemann
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

6.  Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.

Authors:  Elisa Roztocil; Suzanne M Nicholl; Mark G Davies
Journal:  J Surg Res       Date:  2007-07       Impact factor: 2.192

7.  Association between urokinase haplotypes and outcome from infection-associated acute lung injury.

Authors:  John Arcaroli; Jeff Sankoff; Nianjun Liu; David B Allison; James Maloney; Edward Abraham
Journal:  Intensive Care Med       Date:  2007-11-10       Impact factor: 17.440

8.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

9.  Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice.

Authors:  Annika Jögi; Birgitte Rønø; Ida K Lund; Boye S Nielsen; Michael Ploug; Gunilla Høyer-Hansen; John Rømer; Leif R Lund
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

10.  Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells.

Authors:  Marc Tjwa; Nicolai Sidenius; Rute Moura; Sandra Jansen; Koen Theunissen; Annapaola Andolfo; Maria De Mol; Mieke Dewerchin; Lieve Moons; Francesco Blasi; Catherine Verfaillie; Peter Carmeliet
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.